SCHEMBL7075587

SCHEMBL7075587

CCOC(=O)CC1=Cc2ccc(OC)cc2CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.44
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
MCHR1 Q99705 1/20 0.40
PTGS2 P35354 2/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NLRP3 Q96P20 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7071372 0.90 PPARG (0.41) PPARGMAPTALDH1A1L3MBTL1NLRP3
SCHEMBL8096734 0.83 PPARG (0.42) PPARGCYP11B2MCHR1PTGS2HSD17B10
SCHEMBL11469458 0.79 CYP11B1 (0.48) CYP11B1CYP11B2MCHR1PTGS2HSD17B10
SCHEMBL8099968 0.79 MCHR1 (0.42) MCHR1HSD17B10MAPTALDH1A1L3MBTL1
SCHEMBL4622221 0.79 MCHR1 (0.44) CYP11B1CYP11B2MCHR1PTGS2HSD17B10
SCHEMBL636380 0.78 MCHR1 (0.45) CYP11B1CYP11B2MCHR1PTGS2HSD17B10
SCHEMBL11006963 0.77 POLB (0.43) PPARGCYP11B1CYP11B2MCHR1PTGS2
SCHEMBL7355043 0.76 MCHR1 (0.44) CYP11B1CYP11B2MCHR1PTGS2HSD17B10
Hydrochloric Acid SCHEMBL11006960 0.76 POLB (0.43) PPARGCYP11B1CYP11B2MCHR1PTGS2
SCHEMBL11666679 0.74 S1PR1 (0.49) CYP11B1CYP11B2MCHR1PTGS2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed
EP-1198231-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-24 EP disclosed
WO-2001007036-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 PPARG 2249/4885CYP11B1 3775/4885CYP11B2 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.